Compare · DFTX vs OBIO
DFTX vs OBIO
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Orchestra BioMed Holdings Inc. (OBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and OBIO operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $2.37B, about 10.0x OBIO ($237.7M).
- DFTX has been more active in the news (10 items in the past 4 weeks vs 6 for OBIO).
- OBIO has more recent analyst coverage (9 ratings vs 4 for DFTX).
- Company
- Definium Therapeutics Inc.
- Orchestra BioMed Holdings Inc.
- Price
- $21.71-0.80%
- $3.94-1.00%
- Market cap
- $2.37B
- $237.7M
- 1M return
- +5.34%
- -
- 1Y return
- +213.73%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 10
- 6
- Recent ratings
- 4
- 9
Latest DFTX
- Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
- SEC Form DEFA14A filed by Definium Therapeutics Inc.
- SEC Form DEF 14A filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments
- Stifel initiated coverage on Definium Therapeutics with a new price target
- Piper Sandler initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
Latest OBIO
- FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
- Amendment: SEC Form SCHEDULE 13D/A filed by Orchestra BioMed Holdings Inc.
- Large owner Rtw Investments, Lp exercised 1,250,032 in-the-money shares at a strike of $0.00 and sold $132 worth of shares (32 units at $4.13) (SEC Form 4)
- SEC Form DEFA14A filed by Orchestra BioMed Holdings Inc.
- SEC Form DEF 14A filed by Orchestra BioMed Holdings Inc.
- Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
- SEC Form 4 filed by Sherman Darren
- SEC Form 4 filed by Aiello Joshua
- SEC Form 4 filed by Hochman David P
- Officer Hochman David P bought $42,900 worth of shares (10,000 units at $4.29), increasing direct ownership by 0.93% to 1,086,467 units (SEC Form 4)